A double‐blind multicentre comparison of remoxipride, at two dose levels, and haloperidol

Abstract

Patris M, Agussol P, Alby JM, et al. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatr Scand 1990; 82 (Supp1.358): 78-82.Abstract: A total of 186 patients who met the DSM-I11 criteria for schizophrenia were admitted to a double-blind randomized multicentre trial in which the efficacy and safety of remoxipride at two dose levels was compared with those of haloperidol. Over a period of six weeks the patients received remoxipride 100-300 mg/day (n=60), remoxipride 200-600 mg/day (n=61), or haloperidol 10-30 mglday (n=64). There was no significant difference between the three treated groups with regard to the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scores obtained. Remoxipride, at both dosage ranges used, thus had comparable therapeutic efficacy to that of haloperidol. In contrast, extrapyramidal symptoms occurred significantly more frequently in the group treated with haloperidol. Laboratory tests and cardiovascular investigations showed no specific drug effect in any of the treated patients. Remoxipride is thus effective in acute treatment of schizophrenia at both dosage levels and has an advantage over haloperidol in neurological acceptability.Remoxipride is a substituted benzamide, which in-vitro

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

“…We rejected the assertion of Geddes et al 1 that the SGAs were equally efficacious as a homogeneous group because the amount of variance attributable to the different SGAs was large (Q 9 =58.8; P=10 −8 random-effects model). Aripiprazole, [112][113][114] quetiapine, 108,[115][116][117][118] remoxipride, [119][120][121][122][123][124][125][126][127][128][129][130][131][132][133][134][135] sertindole, [109][110][111][136][137][138] and ziprasidone 107,[139][140][141][142] show similar efficacy to FGAs in the sense that the improvement scores produced by these SGAs were not statistically significantly better than those of FGAs (Table 2). Failure to find a statistically significant difference does not prove that these drugs are equal to FGAs because there is a possibility that further studies could demonstrate this.…”

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2 Receptor Antagonist

“…In general, clinical studies (for a review see refs. 91,124) showed that remoxipride had clinical efficacy similar to that of haloperidol (2,4,21,58,60,67,77,93,97) or chlorpromazine (15,16,48,76,96), although it produced less extrapyramidal side effects (EPS) than standard treatments. Remoxipride was found to be superior to placebo in maintaining remission over a 6-month period.…”

BMY-14802 reversed the ? receptor agonist-induced neck dystonia in rats

“…Indeed, early clinical trials showed that these drugs induced less extrapyramidal side effects than typical neuroleptics such as haloperidol (Guy et al, 1983;Chouinard and Annable, 1984;Lindstrom et al, 1985;McCreadie et al, 1985;Schwarcz et al, 1985;Patris et al, 1990;Lapierre et al, 1992;Gewirtz et al, 1994). However, receptor binding studies revealed that these atypical neuroleptics also have a significant affinity for a receptors (Largent et al, 1988).…”